children pediatric classroom

Bristol-based children’s incontinence charity marks its 30th anniversary

The UK’s only charity dedicated to bowel and bladder health in children and teenagers in the UK – based in Bristol – today (May 1) marks its 30th anniversary. ERIC has been providing valuable support and advice to parents and children struggling with incontinence, a condition that continues to be heavily stigmatised, for more than three decades and has commemorated its big birthday by making the help it provides even more accessible.  In the UK an estimated 900,000, or 1 in 12, 5-19 year olds suffer from bowel and bladder conditions – including bedwetting, daytime wetting, constipation and soiling. Read more.

Source: BristolLive, May 1, 2019

drugs for overactive bladder (OAB)

TARIS Bio Initiates New Clinical Study of TAR-302 in Overactive Bladder

TARIS Bio, a biopharmaceutical company developing transformational therapies to treat people with debilitating urological disorders, announced today the initiation of a new clinical investigation of TAR-302 for the treatment of overactive bladder (OAB). As a new follow-on arm of the company’s previously concluded Phase 1b trial, the study is designed to investigate the safety, tolerability, and preliminary efficacy of a single 12-week dose of the system, doubling the previous treatment experience and representing a duration that better meets the real-world needs of patients with this serious and chronic disease. Read more.

Source: Yahoo! Finance, May 1, 2019

nurse and patient

AUA Updates Overactive Bladder Guideline

The American Urological Association (AUA) announced that it has updated its guideline for the diagnosis and treatment of non-neurogenic overactive bladder (OAB) in adult patients.  As a result of a 2018 systematic review of recently published studies, AUA modified guideline statement 12 to say clinicians may consider combination therapy with an antimuscarinic agent and beta3-andrenoceptor agonist for patients who are refractory to monotherapy with either of those medications. Read more.

Source: Renal & Urology News, April 25, 2019

student studying

Incontinence: ‘Lack of Support’ for Older Children

For Gruff, double incontinence has made some days at secondary school an anxious and humiliating experience.  Campaigners claim there is a lack of support in Wales, estimating that 1 in 10 UK children suffer bedwetting, daytime accidents and constipation.  The Welsh Government said it expected health boards to provide specialist-led continence services for under-19s. Read more.

Source: BBC News, April 25, 2019

northshore supply

NorthShore’s Revolutionary Adult Diaper is Designed to Reduce Stigma Surrounding Heavy Incontinence

Over 80 million adults in the U.S. manage some level of urinary or bowel incontinence, and many millions more will be faced with leaks and loss of control later in life. The good news is many of these symptoms are treatable or can be managed using incontinence pads bought in stores. But what if that isn’t enough? For people who have heavy incontinence and need stronger, more absorbent products than those found in stores, their options have been limited to clinical hospital-like briefs. Until now. Earlier this year, NorthShore Care Supply, a Buffalo Grove Illinois-based company founded to empower those with heavy bladder or bowel leakage, unveiled its popular SupremeLite™ absorbent brief, now in vibrant shades of blue, green and purple. Read more.

Source: Newswire.com., April 23, 2019

pelvic vaginal mesh stress urinary incontinence Polypropylene vaginal mesh

FDA Halts All Sales of Pelvic Mesh Products Tied to Injuries in Women

The U.S. Food and Drug Administration on Tuesday announced a ban on the sale of all pelvic mesh products.  The surgical mesh is typically used to repair pelvic organ prolapse (POP) and incontinence, but reported side effects have included permanent incontinence, severe discomfort and an inability to have sex.  “In order for these mesh devices to stay on the market, we determined that we needed evidence that they worked better than surgery without the use of mesh to repair POP,” said Dr. Jeffrey Shuren, director of the FDA’s Center for Devices and Radiological Health. “That evidence was lacking in these premarket applications, and we couldn’t assure women that these devices were safe and effective long term.” Read more.

Source: HealthDay News, April 16, 2019

business buildings

INNOVO Transcutaneous Electrical Stimulator for Urinary Incontinence Coming to U.S.

Atlantic Therapeutics, a company out of Galway, Ireland, will soon be releasing its INNOVO transcutaneous electrical stimulator to treat stress urinary incontinence in women. The device was FDA approved late last year as the first transcutaneous stimulator with such an indication. It delivers electric current through the body toward muscles that control the pelvic floor, which in turn can help maintain continence.  The technology provides women a non-invasive option that, in a clinical trial, demonstrated that 87% of women were dry or nearly so after a three month treatment. 80% of the women studied had results after only a month or therapy.  Read more.

Medgadget, April 11, 2019

product approval introduction

InControl Medical Wins FDA Clearance for Attain: The First Over-the-Counter, At-Home Device for the Treatment of Urinary and/or Fecal Incontinence in Women

InControl Medical wins FDA clearance for new Attain, the first over-the-counter (OTC) non-implantable muscle stimulator designed for at-home use to help treat the approximately 60 million women in the U.S. suffering with stress, urge, mixed urinary incontinence and/or bowel incontinence.  This is good news for all those affected by urinary and/or involuntary bowel leakage that can increase with age: 20% -30% of young women, 30%-40% of middle-aged women, and up to 50% of older women suffer from incontinence.  It’s time to talk about this taboo topic before diapers become the newest accessory in the Nike store. So, strengthen your calves and abs, but don’t forget to strengthen your pelvic floor muscles too, says Lauren Streicher, M.D., Medical Director of the Northwestern Medicine Center for Sexual Health and Menopause and Clinical Professor of Obstetrics and Gynecology at Northwestern University. All kidding aside, many of my patients who suffer with urinary incontinence, can also have leaky bowel, and truly suffer in silence and embarrassment. Post-partum, anal or rectal cancer, and the natural aging process can cause incontinence. Thankfully, many patients respond well to pelvic-floor electrical stimulation and biofeedback as a first-line treatment, before considering surgery or medication. Attain is a small, painless, easy to use medical device for women to self-treat in the privacy of their own home, reducing or eliminating the need for pads or diapers. Read more.

Source: Global Banking & Finance Review, March 26, 2019

women friends

Behavioral Therapy Superior to Drugs Alone for Urinary Incontinence

Behavioral therapies relieve stress, urgency, and mixed urinary incontinence (UI) more effectively than drug monotherapies in nonpregnant women.  In a new systematic review and network meta-analysis (NMA) of 84 randomized trials published in theAnnals of Internal Medicine, most interventions including combination therapies improved or resolved women’s symptoms better than no treatment, whether sham or watchful waiting, Ethan Balk, MD, MPH, of Brown University in Providence, Rhode Island, and colleagues reported. Hormones and periurethral bulking agents appeared less than effective, however. Read more.

Source: Renal & Urology News, March 20, 2019

drugs for overactive bladder (OAB)

First Big Test Approaches for Urovant

Investors who backed Urovant’s $140m flotation last September will soon find out whether the money was well spent. Before the end of March the company will release topline pivotal data on the overactive bladder project vibegron, a β3-adrenergic receptor agonist licensed from Merck & Co, and a positive result should allow regulatory filings to follow.  It seems likely that the trial will hit: Merck successfully conducted a large phase IIb study of vibegron a few years ago, and a similar compound is already on the market in the shape of Myrbetriq, which has been sold by Astellas since 2011. This well-established product has only four years of US patent life left, so if Urovant has any chance of building vibegron into a similarly large product it needs to prove that its contender is both safer and more effective.   Read more.

Source: Evaluate, March 12, 2019